Contrasting fortunes for Biogen Idec and Sanofi in the EU
This article was originally published in Scrip
Executive Summary
On March 22, 2013, the EMA's Committee for Medicinal Products for Human Use (CHMP) provided positive opinions on two new oral treatments for relapsing-remitting multiple sclerosis (RRMS), Tecfidera (dimethyl fumarate; Biogen Idec) and Aubagio (teriflunomide; Sanofi). Both drugs have been recommended for marketing authorization in the EU and can be expected to be commercially available during 2013.